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Abstract: 
Ricin is known as a potent toxin against animals. It consists of two chains, Ricin Toxin A (RTA) and Ricin Toxin B (RTB). The toxic 
effect is known to be caused by RTA. Inhibitors for RTA with less efficiency have been reported. Hence, it is of interest to identify 
new inhibitors. Virtual screening methods (computer aided drug designing) to find similar molecules in drug database were used 
for screening new inhibitors against RTA. We used the structure of RTA in complex with Pteroic acid (PDB code: 1BR6) as target 
molecule. Ligand based virtual screening approach was used in which the known inhibitory molecule Pteroic acid (PTA) served as 
a template to identify similar ligands from the ZINC database. These ligands were docked inside the binding pocket of RTA by 
using the MVD (Molegro Virtual Docker). This approach successfully identified six novel compounds. These docked ligands 
interacted with Asn78, Ala79, Val81, Gly121 and Ser176 amino acids, which are key residues of the RTA active site. Three 
compounds in particular, ZINC05156321 (6, 7 diphenylpteridin-4-ol), ZINC05156324 (6, 7-bis (3-fluorophenyl) pteridin-4-ol) and 
ZINC08555900 (6, 7-bis (4-fluorophenyl)-1H-pteridin-4-one), showed higher binding affinity in comparison to PTA, with high 
interaction energy, better space fitting and electrostatic interactions.  These molecules should be tested for in vitro and in vivo 
activities in future for consideration as effective inhibitors. 
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Background:  
Ricin is a powerful cytotoxic protein. The tertiary (30) structure 
o f  R i c i n  i s  a  g l o b u l a r  a n d  g l y c o s y l a t e d  h e t e r o d i m e r ,  w i t h  a n  
approximate molecular weight of 60-65 kDa (Figure 1)  [1]. It 
consists of two chains namely Ricin Toxin A Chain (RTA) and 
Ricin Toxin B Chain (RTB). RTA and RTB are of approximately 
similar molecular weight i.e. 32 kDa and 34 kDa respectively. 
Ricin A Chain (Figure 1) is an N-glycoside hydrolase made up 
of 267 amino acids [2]. It has three structural domains in which 
approximately 50% of the polypeptides are arranged into α-
helices and β-sheets [3]. The three domains form a prominent 
cavity that has formed an active site of RTA. Ricin B Chain 
(Figure 1a) is basically a lectin consisting of 262 amino acids 
which can bind to the terminal galactose residues on cell 
surfaces  [4]. RTB forms a bilobal, barbell-like structure that 
lacks α-helices and β-sheets, although individual lobes consist 
of three subdomains. Ricin functions as a cytotoxin, in the 
process where RTA is reductively cleaved from RTB in order to 
remove a steric block, after the cleaving active site is exposed on 
RTA [5]. N-glycosidase activity of the ricin protein was studied 
[6]. In eukaryotic ribosomes RTA specifically and irreversibly 
cleaves the glycosidic bond of adenine at position 4324 within 
the 28S rRNA of the 60S subunit. However, the phosphodiester 
backbone of the RNA will remain intact [7]. RTA targets 
adenine at position 4324 (A4324) of the highly conserved 
sequence, which is about 12 nucleotides long and universally BIOINFORMATION  open access 
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found in eukaryotic ribosomes. This highly conserved sequence, 
5’-AGUACGAGAGGA-3’, is known as the SRL (Sarcin-Ricin 
Loop) and is important for binding elongation factors during 
protein synthesis [8]. The depurination event caused by RTA 
rapidly and completely inactivates the ribosome, which results 
in toxicity, in turn leads to inhibition of protein synthesis. 
Approximately 1500 ribosomes are depurinated by a single 
RTA molecule in the cytosol within a minute [9]. There are 
several invariable amino acid residues in the active site of RTA 
that are involved in the depurination reaction of ribosomal 
RNA [10]. The exact mechanism of the depurination event is 
unknown but the key amino acid residues that are identified to 
be involved in depurination reaction includes Arginine (ARG) 
at position 180, Glutamic acid (GLU) at position 177 and 
Tyrosine (TYR) at positions 80 and 123. In particular, ARG180 
and GLU177 are involved in the catalytic mechanism, but not in 
substrate binding [11]. This has been proved with enzyme 
kinetic studies involving RTA mutants [5]. PTA and its 
derivatives had been extensively studied, found proper binding 
with RTA and with good biological activity [12]. Hence, we 
have selected PTA as a seed molecule to perform ligand based 
virtual screening. Ligand based virtual screening method will 
give us number of molecules similar to the seed molecule [13]. 
Ligand-based techniques derive knowledge from given active 
molecule/molecules that are known to bind to the desired 
target molecule, to use this knowledge search the candidate 
molecules in large databases with similar properties [14]. This 
can be done by various methods, including similarity and 
substructure searching [15], 3D shape matching [16] or 
pharmacophore matching [17].  In this study, we have selected 
similarity and substructure based searching approach for 
screening the molecules with similar properties. 
 
Methodology: 
X-ray crystallographic structure of target: 
The 3-Dimensional crystal structure of Ricin Toxin-A Chain 
(RTA) in complex with Pteroic Acid (PTA) inhibitor (PDB code: 
1BR6) was selected from the Protein DataBank (PDB) [18], as 
the receptor/target model in virtual screening process. 
 
Ligand ZINC database (Version - Eight): 
ZINC database [19] has been used screening.  ZINC contains 
over 13 million compounds in 3-Dimensional structural format 
and ready-to-dock formats available for docking [20].  
 
Pocket-Finder: 
Pocket-Finder [21] was used for active site (pocket) detection on 
RTA protein. 
 
Molegro Virtual Docker (Version- 3.2): 
In this work Molegro Virtual Docker (MVD) [22] has been used 
for the prediction of protein-ligand interactions study [23]. 
 
Results: 
Prediction of active site on RTA: 
Active site of RTA was predicted using the Pocket-Finder 
program  (Figure 1b). Active site consists of following amino 
acid residues  ASN78, TYR 80, VAL81, PHE93, GLY121, 
ASN122, TYR123, ARG134, ILE172, GLU177, ARG180, GLU208, 
ASN209 and TRP211 [10]. Results from earlier investigators had 
represented that active site of Ricin Toxin-A chain (RTA) has 
been complexed with ligand PTA (Figure 1b). 
 
Figure 1: (a) Crystallographic structure of Ricin (Ricin-A chain 
is shown in blue color and Ricin-B chain is shown in red color), 
(b) Active site (Blue color) of Ricin Toxin A chain (RTA) 
predicted by Pocket-Finder, (c) Hydrogen bond interactions of 
Pteroic acid within the binding pocket of RTA, (d) Hydrogen 
bond interactions of ZINC05156324 (6, 7-bis (3-fluorophenyl) 
pteridin-4-ol) within the binding pocket of RTA, (e) Hydrogen 
bond interactions of ZINC08555900 (6, 7-bis (4-fluorophenyl)-
1H-pteridin-4-one) within the binding pocket of RTA, (f) 
Hydrogen bond interactions of ZINC05156321 (6, 7 
diphenylpteridin-4-ol) within the binding pocket of RTA. 
 
Virtual screening on ZINC database: 
Before screening ZINC database, the docking protocol was 
validated. PTA ligand was re-docked within the binding pocket 
of RTA (PDB ID: 1BR6) to obtain the docking based affinity 
information. The ZINC database was searched on the basis of 
structure of PTA in result of which 34 similar compounds were 
found. All these compounds were docked with Molegro Virtual 
Docker. Six high ranked compounds were then selected on the 
basis of their interaction energies, hydrogen bonding and 
internal energies etc., as described in Table 1  (see 
Supplementary material). Three molecules were then selected 
for structural docking with RTA protein, whose binding 
energies were more than pteroic acid binding energy. 
 
Depiction of binding mode of Pteroic Acid (PTA) within the 
active site of RTA: 
Interactions of Pteroic Acid (PTA) in the binding pocket of RTA 
are shown in Figure 1c. Pteroic Acid showed seven hydrogen 
bond interactions within the active site of RTA. ARG180 formed 
two hydrogen bonds with O22 of PTA (bond lengths are 2.57 Å BIOINFORMATION  open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 7(2): 46-51 (2011)  48   © 2011 Biomedical Informatics
 
and 2.96 Å), SER176 also forms a hydrogen bond with O22 of 
PTA (bond length is 3.43 Å), O19 of PTA formed a hydrogen 
bond with ASN78 (bond length is 2.77 Å), VAL81 formed a 
hydrogen bond with N5 of PTA (bond length is 3.04 Å) and 
GLY121 formed two hydrogen bonds with N3 and N5 of PTA 
(bond lengths are 2.57 Å and 2.96 Å respectively). 
 
Binding studies of top three selected compounds after virtual 
screening: 
Binding of 6, 7- Bis (3-fluorophenyl) pteridin-4-ol 
(ZINC05156324) and RTA is shown in Figure 1d. ZINC05156324 
also formed seven hydrogen bonds within the active site of 
R T A .  I t  f o r m e d  t w o  h y d r o g e n  b o n d s  a t  O 1 7  f r o m  A R G 1 8 0  
(bond lengths are 3.24 Å and 2.80 Å) and two hydrogen bonds 
at N12 with ARG180 (bond lengths are 3.19 Å and 2.95 Å) 
whereas, O17 formed one hydrogen bond with ALA79 (bond 
length is 2.70 Å), one hydrogen bond is formed by N14 with 
VAL81 (bond length is 2.85 Å). Further SER176 and O17 can act 
as both hydrogen bond donor and acceptor for each other (bond 
length is 3.08 Å).  
 
Interaction between 6, 7-bis (4-fluorophenyl) - 1H- pteridin -4- 
one (ZINC08555900) and RTA is shown in Figure 1e. Seven 
hydrogen bond interactions are found between ZINC08555900 
and RTA. It formed three hydrogen bonds with O13, one from 
SER176 and two from ARG180 (bond lengths are 3.28 Å, 3.27 Å 
and 3.00 Å respectively). It formed two hydrogen bonds at N11 
from ARG180 (bond lengths are 3.10 Å and 3.26 Å) and formed 
one hydrogen bond at N14 from VAL81 and one at N16 from 
GLY121 (bond lengths are 2.79 Å and 3.17 Å respectively). 
Figure 1f illustrates the interaction between 6, 7 diphenyl 
pteridine – 4 - ol (ZINC05156321) and the active site of RTA. 
ZINC05156321 shows seven hydrogen bond interactions within 
the active site of RTA. ZINC05156321 formed a hydrogen bond 
at Ala 79 from O16 (bond length is 2.56 Å) and two hydrogen 
bonds with N11 from Arg180 (bond lengths are 3.05 Å and 2.89 
Å). It has also formed two hydrogen bonds with O16 from 
Arg180 (bond lengths are 3.10 Å and 2.93 Å). Further one 
hydrogen bond is formed by N13 from Val81 (bond length is 
2.85 Å), Ser176 and O16 act as both hydrogen bond donor and 
acceptor for each other (bond length is 3.29 Å). 
 
Discussion: 
Novel RTA inhibitors help in the treatment of Racinin based 
toxicity effectively (Figure 1a & 1b). Pteroic acid (PTA) has been 
proved to be one of such inhibitors. Interestingly, its docked 
structural information is also available. It is known that the 
Pterin ring of PTA inhibitor binds in the active site of RTA and 
forms hydrogen bonds with the active site residues [12]. Hence, 
virtual screenings were performed on RTA active site and 34 
similar molecules have been found. Out of the 34 molecules, six 
molecules were selected based on binding energies, dock scores, 
interaction energies, HBond energy, VdW and internal energy 
of poses, number of hydrogen bonds etc., as shown in Table 1. 
The six ligands were docked deep inside the binding pocket of 
RTA. Three molecules were then selected (Figure 1c, 1d, 1e & 
1f) based on their resemblance of similar orientation, as 
observed with Pteroic acid ligand [12] and having more binding 
energies than PTA. PTA formed seven hydrogen bonds with all 
surrounding residues of ASN78, VAL81, GLY121, SER176 and 
ARG180 with interaction energy of -138.4 Kcal/mole. It was 
spatially fit in to the active site with good electrostatic 
interaction. Whereas, best ranked ZINC05156324 (6, 7-bis (3-
fluorophenyl) pteridin-4-ol) has been found to be potential 
inhibitor upon all the molecules by interacting with 
surrounding amino acids like ALA 79, VAL 81, SER 176 and 
ARG 180 by forming hydrogen bonds. It has formed seven 
hydrogen bonds with high interaction energy of -154.625, also 
with better electrostatic interaction and also spatially fit. Rest of 
the two molecules showed high interaction energies when 
compared to PTA with residues like ALA 79, VAL 81, GLY 121, 
SER 176 and ARG 180, both of the molecules showed seven 
hydrogen bonds approximately with -144.00 interaction 
energies. Hence, the above said three molecules can be 
considered as potential RTA inhibitors. The above said 
molecules may function as effective inhibiters because they are 
exactly binding with active site of RTA, which has a role in 
binding with ribosome and for RNA depurination function [12]. 
They may be tested on in vitro and in vivo conditions. As per 
earlier reports Miller et al., (2002) designed RTA inhibitory 
molecules based on structure of the RTA active site and also 
experimentally selected highly soluble molecules as Ricin 
inhibitors [24]. Robertus et al., (2008) has developed molecules 
based on RTA (Ricin Toxin A chain) active site structure based 
virtual screening. Whereas in our work ligand structure (PTA) 
based similarity [25]  search approach (virtual screening) has 
been implemented on ZINC database. 
 
Conclusion: 
Virtual screening methods are widely used for reducing the cost 
and time of drug discovery process. We show the identification 
of six new compounds as potent inhibitor of RTA using virtual 
screening. Nonetheless, these molecules should be tested for in 
vitro and in vivo activities in future for consideration as effective 
inhibitors. 
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Supplementary material: 
 
Table 1: Top six virtually screened compounds presented after Ligand based Virtual screening on the basis of various scoring 
function and their binding affinities. 
S. No.  Name of the 
compounds 
Name & Scores of ligands  2D/ 3D Structure of ligands 
1.    Reference Ligand  Ligand: Pteroic acid 
   
 
IUPAC Name: p-((2-amino-4 hydroxypteridin-6-yl) 
methylamino) benzoic acid 
MolDock Score: -123.39 
Rerank Score: -105.799 
Interaction Energy (protein - ligand): -138.4 
HBond Energy: -13.9455 
VdW (LJ12-6): -44.168 
Internal Energy of Pose: 13.0239 
LE1: -5.36478 
LE3: - 4.59997 
No. of hydrogen bonds: 7 
2.    VS1  Ligand: ZINC05156324 
   
 
 
IUPAC Name: 6,7-bis (3-fluorophenyl) pteridin-4-ol 
MolDock Score:- 144.654 
Rerank Score: -108.126 
Interaction Energy (protein - ligand): -154.625 
HBond Energy: -14.6695 
VdW (LJ12-6): -33.7239                                                                        
Internal Energy of Pose: 9.97131 
LE1: -5.78616 
LE3: -4.32505 
No. of hydrogen bonds: 7 
3.    VS2  Ligand: ZINC08555900 
   
 
IUPAC Name: 6,7-bis (4-fluorophenyl)-1H-pteridin-4-one 
MolDock Score: -143.099 
Rerank Score: -104.7 
Interaction Energy (protein - ligand): -153.835 
HBond Energy: -13.3851 
VdW (LJ12-6): -27.6388 
Internal Energy of Pose: 10.7363 
LE1: -5.72394 
LE3: -4.18801 
No. of hydrogen bonds: 7 
4.    VS3  Ligand: ZINC05156321 
 
IUPAC Name: 6,7 diphenylpteridin-4-ol 
MolDock Score: -128.914 
Rerank Score: -101.851 
Interaction Energy (protein - ligand): -147.527 
HBond Energy: -14.1271 
VdW (LJ12-6): -35.0622 
Internal Energy of Pose: 18.6138 
LE1: -5.60494 BIOINFORMATION  open access 
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LE3: -4.4283 
   
No. of hydrogen bonds: 7 
5.    VS4  Ligand: ZINC06265824 
   
 
IUPAC Name: 8-(dimethylamino)-2-sulfanylidene-1H-
benzo[g] pteridin-4-one 
MolDock Score: 
Rerank Score: -100.987 
Interaction Energy (protein - ligand): -135.947 
HBond Energy: -15.1312 
VdW (LJ12-6): -38.6218 
Internal Energy of Pose: 17.1856 
LE1: -6.25058 
LE3: -5.31511 
No. of hydrogen bonds: 8 
6.    VS5  Ligand: ZINC11330429 
   
 
IUPAC Name: 2-amino-6-methyl-7-(1H-pyrrol-2-yl)-1H-
pteridin-4-one 
MolDock Score: -121.338 
Rerank Score: -103.189 
Interaction Energy (protein - ligand): -135.766 
HBond Energy: -14.0941 
VdW (LJ12-6): -38.9823 
Internal Energy of Pose: 14.4286 
E-Inter (protein - ligand): -135.766 
LE1: -6.74099 
LE3: -5.73274 
No. of hydrogen bonds: 8 
7.    VS6  Ligand: ZINC05973848 
   
 
IUPAC Name: (2-amino-4-oxo-1H-pteridin-6-yl) methyl 
dihydrogen phosphate 
MolDock Score: -116.886 
Rerank Score:-102.323 
Interaction Energy (protein - ligand): -130.448 
HBond Energy: -14.3559 
VdW (LJ12-6): -35.1714 
Internal Energy of Pose: 13.5625 
LE1: -6.49366 
LE3: -5.68463 
No. of hydrogen bonds: 9 
 
 
 
 
  
 